IgA nephropathy (IgAN), the most prevalent primary glomerulonephritis worldwide, carries a considerable lifetime risk of kidney failure. Clinical manifestations of IgAN vary from asymptomatic with microscopic or intermittent macroscopic haematuria and stable kidney function to rapidly progressive glomerulonephritis. IgAN has been proposed to develop through a 'four-hit' process, commencing with overproduction and increased systemic presence of poorly O-glycosylated galactose-deficient IgA1 (Gd-IgA1), followed by recognition of Gd-IgA1 by antiglycan autoantibodies, aggregation of Gd-IgA1 and formation of polymeric IgA1 immune complexes and, lastly, deposition of these immune complexes in the glomerular mesangium, leading to kidney inflammation and scarring. IgAN can only be diagnosed by kidney biopsy. Extensive, optimized supportive care is the mainstay of therapy for patients with IgAN. For those at high risk of disease progression, the 2021 KDIGO Clinical Practice Guideline suggests considering a 6-month course of systemic corticosteroid therapy; however, the efficacy of systemic steroid treatment is under debate and serious adverse effects are common. Advances in understanding the pathophysiology of IgAN have led to clinical trials of novel targeted therapies with acceptable safety profiles, including SGLT2 inhibitors, endothelin receptor blockers, targeted-release budesonide, B cell proliferation and differentiation inhibitors, as well as blockade of complement components.

Department of Cardiovascular Sciences University of Leicester Leicester UK

Department of Internal Medicine Nephrology and Transplantation Erasmus Medical Center Rotterdam Netherlands

Department of Nephrology 1st Faculty of Medicine and General University Hospital Charles University Prague Czech Republic

Department of Nephrology and Clinical Immunology RWTH Aachen University Hospital Aachen Germany

Department of Nephrology School of Medicine University of Ioannina Ioannina Greece

Department of Pathology RWTH Aachen University Aachen Germany

Division of Nephrology Department of Medicine University of Hong Kong Hong Kong China

Zobrazit více v PubMed

Pattrapornpisut, P., Avila-Casado, C. & Reich, H. N. IgA nephropathy: core curriculum 2021. Am. J. Kidney Dis. 78, 429–441 (2021). PubMed DOI

Berthoux, F. et al. Predicting the risk for dialysis or death in IgA nephropathy. J. Am. Soc. Nephrol. 22, 752–761 (2011). PubMed DOI PMC

Jarrick, S. et al. Mortality in IgA nephropathy: a nationwide population-based cohort study. J. Am. Soc. Nephrol. 30, 866–876 (2019). PubMed DOI PMC

Moriyama, T. et al. Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS ONE 9, e91756 (2014). PubMed DOI PMC

Okonogi, H. et al. A grading system that predicts the risk of dialysis induction in IgA nephropathy patients based on the combination of the clinical and histological severity. Clin. Exp. Nephrol. 23, 16–25 (2019). PubMed DOI

Suzuki, H. et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J. Clin. Invest. 118, 629–639 (2008). PubMed PMC

Suzuki, H. et al. The pathophysiology of IgA nephropathy. J. Am. Soc. Nephrol. 22, 1795–1803 (2011). PubMed DOI PMC

Xin, G. et al. Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features. J. Nephrol. 26, 683–690 (2013). PubMed DOI

Zhai, Y. L. et al. Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy. Medicine 95, e3099 (2016). PubMed DOI PMC

Lafayette, R. et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet 402, 859–870 (2023). PubMed DOI

Wheeler, D. C. et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 100, 215–224 (2021). PubMed DOI

Heerspink, H. J. L. et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet 401, 1584–1594 (2023). PubMed DOI

Rodrigues, J. C., Haas, M. & Reich, H. N. IgA nephropathy. Clin. J. Am. Soc. Nephrol. 12, 677–686 (2017). PubMed DOI PMC

Xie, Y. & Chen, X. Epidemiology, major outcomes, risk factors, prevention and management of chronic kidney disease in China. Am. J. Nephrol. 28, 1–7 (2008). PubMed DOI

Schena, F. P. & Nistor, I. Epidemiology of IgA nephropathy: a global perspective. Semin. Nephrol. 38, 435–442 (2018). PubMed DOI

Okpechi, I. G. et al. Epidemiology of histologically proven glomerulonephritis in Africa: a systematic review and meta-analysis. PLoS ONE 11, e0152203 (2016). PubMed DOI PMC

Nair, R. & Walker, P. D. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney Int. 69, 1455–1458 (2006). PubMed DOI

Kiryluk, K., Novak, J. & Gharavi, A. G. Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies. Annu. Rev. Med. 64, 339–356 (2013). PubMed DOI

Sanchez-Rodriguez, E., Southard, C. T. & Kiryluk, K. GWAS-based discoveries in IgA nephropathy, membranous nephropathy, and steroid-sensitive nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 16, 458–466 (2021). PubMed DOI

Feehally, J. et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J. Am. Soc. Nephrol. 21, 1791–1797 (2010). PubMed DOI PMC

Gharavi, A. G. et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat. Genet. 43, 321–327 (2011). PubMed DOI PMC

Kiryluk, K. & Novak, J. The genetics and immunobiology of IgA nephropathy. J. Clin. Invest. 124, 2325–2332 (2014). PubMed DOI PMC

Kiryluk, K. et al. Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. Nat. Genet. 55, 1091–1105 (2023). PubMed DOI

Magistroni, R., D’Agati, V. D., Appel, G. B. & Kiryluk, K. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int. 88, 974–989 (2015). PubMed DOI PMC

Lai, K. N. et al. IgA nephropathy. Nat. Rev. Dis. Primers 2, 16001 (2016). PubMed DOI

Shen, P. et al. Clinicopathological characteristics and outcome of adult patients with hematuria and/or proteinuria found during routine examination. Nephron Clin. Pract. 103, c149–c156 (2006). PubMed DOI

Moldoveanu, Z. et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int. 71, 1148–1154 (2007). PubMed DOI

Allen, A. C., Bailey, E. M., Barratt, J., Buck, K. S. & Feehally, J. Analysis of IgA1 O-glycans in IgA nephropathy by fluorophore-assisted carbohydrate electrophoresis. J. Am. Soc. Nephrol. 10, 1763–1771 (1999). PubMed DOI

Hiki, Y. et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int. 59, 1077–1085 (2001). PubMed DOI

Xu, L. X. & Zhao, M. H. Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy. Kidney Int. 68, 167–172 (2005). PubMed DOI

Barratt, J., Smith, A. C. & Feehally, J. The pathogenic role of IgA1 O-linked glycosylation in the pathogenesis of IgA nephropathy. Nephrology 12, 275–284 (2007). PubMed DOI

Dotz, V. et al. O- and N-glycosylation of serum immunoglobulin A is associated with IgA nephropathy and glomerular function. J. Am. Soc. Nephrol. 32, 2455–2465 (2021). PubMed DOI PMC

Ohyama, Y., Renfrow, M. B., Novak, J. & Takahashi, K. Aberrantly glycosylated IgA1 in IgA nephropathy: what we know and what we don’t know. J. Clin. Med. 10, 3467 (2021). PubMed DOI PMC

Gesualdo, L., Di Leo, V. & Coppo, R. The mucosal immune system and IgA nephropathy. Semin. Immunopathol. 43, 657–668 (2021). A very good review of the role of the mucosal immune system in IgAN. PubMed DOI PMC

Franc, V. et al. Elucidating heterogeneity of IgA1 hinge-region O-glycosylation by use of MALDI-TOF/TOF mass spectrometry: role of cysteine alkylation during sample processing. J. Proteom. 92, 299–312 (2013). DOI

Yamada, K. et al. Down-regulation of core 1 β1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol. Dial. Transpl. 25, 3890–3897 (2010). DOI

Suzuki, H. et al. Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes. J. Biol. Chem. 289, 5330–5339 (2014). PubMed DOI

Xing, Y. et al. C1GALT1 expression is associated with galactosylation of IgA1 in peripheral B lymphocyte in immunoglobulin a nephropathy. BMC Nephrol. 21, 18 (2020). PubMed DOI PMC

Serino, G., Sallustio, F., Cox, S. N., Pesce, F. & Schena, F. P. Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J. Am. Soc. Nephrol. 23, 814–824 (2012). PubMed DOI PMC

Serino, G. et al. Role of let-7b in the regulation of N-acetylgalactosaminyltransferase 2 in IgA nephropathy. Nephrol. Dial. Transpl. 30, 1132–1139 (2015). DOI

Serino, G. et al. In a retrospective international study, circulating miR-148b and let-7b were found to be serum markers for detecting primary IgA nephropathy. Kidney Int. 89, 683–692 (2016). PubMed DOI

Wang, Z. et al. Small RNA deep sequencing reveals novel miRNAs in peripheral blood mononuclear cells from patients with IgA nephropathy. Mol. Med. Rep. 22, 3378–3386 (2020). PubMed PMC

Gale, D. P. et al. Galactosylation of IgA1 is associated with common variation in C1GALT1. J. Am. Soc. Nephrol. 28, 2158–2166 (2017). This study demonstrates that common variation at C1GALT1 influences the Gd-IgA1 level in the population, which is independently associated with risk of progressive IgAN. PubMed DOI PMC

Gharavi, A. G. et al. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J. Am. Soc. Nephrol. 19, 1008–1014 (2008). PubMed DOI PMC

Xie, Y., Chen, X., Nishi, S., Narita, I. & Gejyo, F. Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy. Kidney Int. 65, 1135–1144 (2004). PubMed DOI

Floege, J. & Feehally, J. The mucosa–kidney axis in IgA nephropathy. Nat. Rev. Nephrol. 12, 147–156 (2016). PubMed DOI

Harper, S. J. et al. Expression of J chain mRNA in duodenal IgA plasma cells in IgA nephropathy. Kidney Int. 45, 836–844 (1994). PubMed DOI

Yeo, S. C., Cheung, C. K. & Barratt, J. New insights into the pathogenesis of IgA nephropathy. Pediatr. Nephrol. 33, 763–777 (2018). PubMed DOI

Batra, A., Smith, A. C., Feehally, J. & Barratt, J. T-cell homing receptor expression in IgA nephropathy. Nephrol. Dial. Transpl. 22, 2540–2548 (2007). DOI

Buren, M., Yamashita, M., Suzuki, Y., Tomino, Y. & Emancipator, S. N. Altered expression of lymphocyte homing chemokines in the pathogenesis of IgA nephropathy. Contrib. Nephrol. 157, 50–55 (2007). PubMed

Zachova, K. et al. Galactose-deficient IgA1 B cells in the circulation of IgA nephropathy patients carry preferentially lambda light chains and mucosal homing receptors. J. Am. Soc. Nephrol. 33, 908–917 (2022). PubMed DOI PMC

Kano, T. et al. Mucosal immune system dysregulation in the pathogenesis of IgA nephropathy. Biomedicines 10, 3027 (2022). PubMed DOI PMC

Kawabe, M. et al. Association between galactose-deficient IgA1 derived from the tonsils and recurrence of IgA nephropathy in patients who underwent kidney transplantation. Front. Immunol. 11, 2068 (2020). PubMed DOI PMC

Rovin, B. H. et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 100, 753–779 (2021). This is the KDIGO practice guideline recommended for IgAN. PubMed DOI

Schmitt, R. et al. Tissue deposits of IgA-binding streptococcal M proteins in IgA nephropathy and Henoch–Schönlein purpura. Am. J. Pathol. 176, 608–618 (2010). PubMed DOI PMC

Watanabe, H. et al. Comprehensive microbiome analysis of tonsillar crypts in IgA nephropathy. Nephrol. Dial. Transpl. 32, 2072–2079 (2017).

Park, J. I. et al. Comparative analysis of the tonsillar microbiota in IgA nephropathy and other glomerular diseases. Sci. Rep. 10, 16206 (2020). PubMed DOI PMC

Kiryluk, K. et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat. Genet. 46, 1187–1196 (2014). A large GWA study that suggests that interactions between the host and intestinal pathogens may influence the genetics of IgAN. PubMed DOI PMC

Rehnberg, J., Symreng, A., Ludvigsson, J. F. & Emilsson, L. Inflammatory bowel disease is more common in patients with IgA nephropathy and predicts progression of ESKD: a Swedish population-based cohort study. J. Am. Soc. Nephrol. 32, 411–423 (2021). PubMed DOI

Barratt, J. et al. Why target the gut to treat IgA nephropathy? Kidney Int. Rep. 5, 1620–1624 (2020). PubMed DOI PMC

De Angelis, M. et al. Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). PLoS ONE 9, e99006 (2014). PubMed DOI PMC

Hobby, G. P. et al. Chronic kidney disease and the gut microbiome. Am. J. Physiol. Ren. Physiol. 316, F1211–F1217 (2019). DOI

Sallustio, F. et al. High levels of gut-homing immunoglobulin A DOI

Medzhitov, R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1, 135–145 (2001). PubMed DOI

Donadio, M. E. et al. Toll-like receptors, immunoproteasome and regulatory T cells in children with Henoch–Schönlein purpura and primary IgA nephropathy. Pediatr. Nephrol. 29, 1545–1551 (2014). PubMed DOI

Zheng, N. et al. TLR7 in B cells promotes renal inflammation and Gd-IgA1 synthesis in IgA nephropathy. JCI Insight 5, e136965 (2020). PubMed DOI PMC

Ciferska, H. et al. Does the renal expression of Toll-like receptors play a role in patients with IgA nephropathy? J. Nephrol. 33, 307–316 (2020). PubMed DOI

Li, W. et al. TLR9 and BAFF: their expression in patients with IgA nephropathy. Mol. Med. Rep. 10, 1469–1474 (2014). PubMed DOI

Qin, W. et al. External suppression causes the low expression of the Cosmc gene in IgA nephropathy. Nephrol. Dial. Transpl. 23, 1608–1614 (2008). DOI

Cheema, G. S., Roschke, V., Hilbert, D. M. & Stohl, W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 44, 1313–1319 (2001). PubMed DOI

McCarthy, D. D. et al. Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. J. Clin. Invest. 121, 3991–4002 (2011). PubMed DOI PMC

Goto, T. et al. Increase in B-cell-activation factor (BAFF) and IFN-γ productions by tonsillar mononuclear cells stimulated with deoxycytidyl-deoxyguanosine oligodeoxynucleotides (CpG-ODN) in patients with IgA nephropathy. Clin. Immunol. 126, 260–269 (2008). PubMed DOI

Ye, M. et al. Vibration induces BAFF overexpression and aberrant O-glycosylation of IgA1 in cultured human tonsillar mononuclear cells in IgA nephropathy. Biomed. Res. Int. 2016, 9125960 (2016). PubMed DOI PMC

Shao, J. et al. Capsaicin induces high expression of BAFF and aberrantly glycosylated IgA1 of tonsillar mononuclear cells in IgA nephropathy patients. Hum. Immunol. 75, 1034–1039 (2014). PubMed DOI

Xin, G. et al. Serum BAFF and APRIL might be associated with disease activity and kidney damage in patients with anti-glomerular basement membrane disease. Nephrology 18, 209–214 (2013). PubMed DOI

Muto, M. et al. Toll-like receptor 9 stimulation induces aberrant expression of a proliferation-inducing ligand by tonsillar germinal center B cells in IgA nephropathy. J. Am. Soc. Nephrol. 28, 1227–1238 (2017). PubMed DOI

Takahara, M. et al. A proliferation-inducing ligand (APRIL) induced hyper-production of IgA from tonsillar mononuclear cells in patients with IgA nephropathy. Cell Immunol. 341, 103925 (2019). PubMed DOI

Makita, Y. et al. TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. Kidney Int. 97, 340–349 (2020). PubMed DOI

Suzuki, H. et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J. Clin. Invest. 119, 1668–1677 (2009). PubMed PMC

Tomana, M. et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J. Clin. Invest. 104, 73–81 (1999). PubMed DOI PMC

Tomana, M. et al. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int. 52, 509–516 (1997). PubMed DOI

Suzuki, H. & Novak, J. IgA glycosylation and immune complex formation in IgAN. Semin. Immunopathol. 43, 669–678 (2021). PubMed DOI

Knoppova, B. et al. The origin and activities of IgA1-containing immune complexes in IgA nephropathy. Front. Immunol. 7, 117 (2016). PubMed DOI PMC

Knoppova, B. et al. Pathogenesis of IgA nephropathy: current understanding and implications for development of disease-specific treatment. J. Clin. Med. 10, 4051 (2021). DOI

Moldoveanu, Z. et al. Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathy. J. Autoimmun. 118, 102593 (2021). PubMed DOI PMC

Matsumoto, Y. et al. Identification and characterization of circulating immune complexes in IgA nephropathy. Sci. Adv. 8, eabm8783 (2022). PubMed DOI PMC

Xu, B. et al. Mass spectrometry-based screening identifies circulating immunoglobulinA-α1-microglobulin complex as potential biomarker in immunoglobulin A nephropathy. Nephrol. Dial. Transpl. 36, 782–792 (2021). DOI

van Zandbergen, G. et al. Crosslinking of the human Fc receptor for IgA (FcαRI/CD89) triggers FcR γ-chain-dependent shedding of soluble CD89. J. Immunol. 163, 5806–5812 (1999). PubMed DOI

Launay, P. et al. Fcα receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger’s disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice. J. Exp. Med. 191, 1999–2009 (2000). PubMed DOI PMC

van Dijk, T. B. et al. Cloning and characterization of Fc alpha Rb, a novel Fc alpha receptor (CD89) isoform expressed in eosinophils and neutrophils. Blood 88, 4229–4238 (1996). PubMed DOI

Cambier, A. et al. Soluble CD89 is a critical factor for mesangial proliferation in childhood IgA nephropathy. Kidney Int. 101, 274–287 (2022). PubMed DOI

Berthelot, L. et al. Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J. Exp. Med. 209, 793–806 (2012). PubMed DOI PMC

Jhee, J. H. et al. Circulating CD89-IgA complex does not predict deterioration of kidney function in Korean patients with IgA nephropathy. Clin. Chem. Lab. Med. 56, 75–85 (2017). PubMed DOI

Moura, I. C. et al. Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy. J. Am. Soc. Nephrol. 16, 2667–2676 (2005). PubMed DOI

Ikee, R. et al. Involvement of transglutaminase-2 in pathological changes in renal disease. Nephron Clin. Pract. 105, c139–c146 (2007). PubMed DOI

Moresco, R. N. et al. Urinary myeloid IgA Fc alpha receptor (CD89) and transglutaminase-2 as new biomarkers for active IgA nephropathy and Henoch-Schönlein purpura nephritis. BBA Clin. 5, 79–84 (2016). PubMed DOI PMC

Barratt, J., Feehally, J. & Smith, A. C. Pathogenesis of IgA nephropathy. Semin. Nephrol. 24, 197–217 (2004). PubMed DOI

Molyneux, K. et al. β1,4-galactosyltransferase 1 is a novel receptor for IgA in human mesangial cells. Kidney Int. 92, 1458–1468 (2017). PubMed DOI

Mocsai, A., Ruland, J. & Tybulewicz, V. L. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat. Rev. Immunol. 10, 387–402 (2010). PubMed DOI PMC

McAdoo, S. P. et al. Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression. Kidney Int. 88, 52–60 (2015). PubMed DOI PMC

Kim, M. J. et al. Spleen tyrosine kinase is important in the production of proinflammatory cytokines and cell proliferation in human mesangial cells following stimulation with IgA1 isolated from IgA nephropathy patients. J. Immunol. 189, 3751–3758 (2012). PubMed DOI

Tamouza, H. et al. The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy. Kidney Int. 82, 1284–1296 (2012). PubMed DOI PMC

Makita, Y. et al. Glomerular deposition of galactose-deficient IgA1-containing immune complexes via glomerular endothelial cell injuries. Nephrol. Dial. Transpl. 37, 1629–1636 (2022). DOI

Lai, K. N. et al. Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. Nephrol. Dial. Transpl. 24, 62–72 (2009). DOI

Wang, C. et al. Effect of aggregated immunoglobulin A1 from immunoglobulin A nephropathy patients on nephrin expression in podocytes. Nephrology 14, 213–218 (2009). PubMed DOI

Lai, K. N. et al. Activation of podocytes by mesangial-derived TNF-α: glomerulo-podocytic communication in IgA nephropathy. Am. J. Physiol. Ren. Physiol. 294, F945–F955 (2008). DOI

Chan, L. Y., Leung, J. C., Tsang, A. W., Tang, S. C. & Lai, K. N. Activation of tubular epithelial cells by mesangial-derived TNF-α: glomerulotubular communication in IgA nephropathy. Kidney Int. 67, 602–612 (2005). PubMed DOI

Zambrano, S. et al. Molecular insights into the early stage of glomerular injury in IgA nephropathy using single-cell RNA sequencing. Kidney Int. 101, 752–765 (2022). PubMed DOI

Wu, D. et al. Mesangial C3 deposition and serum C3 levels predict renal outcome in IgA nephropathy. Clin. Exp. Nephrol. 25, 641–651 (2021). PubMed DOI

Nam, K. H. et al. Predictive value of mesangial C3 and C4d deposition in IgA nephropathy. Clin. Immunol. 211, 108331 (2020). PubMed DOI

Zwirner, J. et al. Activated complement C3: a potentially novel predictor of progressive IgA nephropathy. Kidney Int. 51, 1257–1264 (1997). PubMed DOI

Kim, S. J. et al. Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy. PLoS ONE 7, e40495 (2012). PubMed DOI PMC

Mizerska-Wasiak, M. et al. Relationship between serum IgA/C3 ratio and severity of histological lesions using the Oxford classification in children with IgA nephropathy. Pediatr. Nephrol. 30, 1113–1120 (2015). PubMed DOI

Evans, D. J. et al. Glomerular deposition of properdin in Henoch-Schönlein syndrome and idiopathic focal nephritis. Br. Med. J. 3, 326–328 (1973). PubMed DOI PMC

Rauterberg, E. W., Lieberknecht, H. M., Wingen, A. M. & Ritz, E. Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis. Kidney Int. 31, 820–829 (1987). PubMed DOI

Miyazaki, R. et al. Glomerular deposition and serum levels of complement control proteins in patients with IgA nephropathy. Clin. Nephrol. 21, 335–340 (1984). PubMed

Tomino, Y., Endoh, M., Nomoto, Y. & Sakai, H. Double immunofluorescence studies of immunoglobulins, complement components and their control proteins in patients with IgA nephropathy. Acta Pathol. Jpn. 32, 251–256 (1982). PubMed

Segarra, A. et al. Mesangial C4d deposits in early IgA nephropathy. Clin. J. Am. Soc. Nephrol. 13, 258–264 (2018). PubMed DOI

Lee, H. J. et al. Association of C1q deposition with renal outcomes in IgA nephropathy. Clin. Nephrol. 80, 98–104 (2013). PubMed DOI

Tan, L. et al. A multicenter, prospective, observational study to determine association of mesangial C1q deposition with renal outcomes in IgA nephropathy. Sci. Rep. 11, 5467 (2021). PubMed DOI PMC

Chang, S. & Li, X. K. The role of immune modulation in pathogenesis of IgA nephropathy. Front. Med. 7, 92 (2020). DOI

Hiemstra, P. S., Gorter, A., Stuurman, M. E., Es, L. A.van & Daha, M. R. Activation of the alternative pathway of complement by human serum IgA. Eur. J. Immunol. 17, 321–326 (1987). PubMed DOI

Russell, M. W. & Mansa, B. Complement-fixing properties of human IgA antibodies. Alternative pathway complement activation by plastic-bound, but not specific antigen-bound, IgA. Scand. J. Immunol. 30, 175–183 (1989). PubMed DOI

Poppelaars, F., Faria, B., Schwaeble, W. & Daha, M. R. The contribution of complement to the pathogenesis of IgA nephropathy: are complement-targeted therapies moving from rare disorders to more common diseases? J. Clin. Med. 10, 4715 (2021). A very good review of the role of complement in IgAN. PubMed DOI PMC

Guo, W. Y. et al. Glomerular complement factor H-related protein 5 is associated with histologic injury in immunoglobulin A nephropathy. Kidney Int. Rep. 6, 404–413 (2021). PubMed DOI

Poppelaars, F. et al. A family affair: addressing the challenges of factor H and the related proteins. Front. Immunol. 12, 660194 (2021). PubMed DOI PMC

Tortajada, A. et al. Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy. Kidney Int. 92, 953–963 (2017). PubMed DOI

Roos, A. et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J. Am. Soc. Nephrol. 17, 1724–1734 (2006). PubMed DOI

Barratt, J. et al. IgA nephropathy: the lectin pathway and implications for targeted therapy. Kidney Int. 104, 254–264 (2023). A very good review of the role of the lectin pathway in IgAN. PubMed DOI

Faria, B. et al. Arteriolar C4d in IgA nephropathy: a cohort study. Am. J. Kidney Dis. 76, 669–678 (2020). PubMed DOI

Liu, L. L., Jiang, Y., Wang, L. N. & Liu, N. Urinary mannose-binding lectin is a biomarker for predicting the progression of immunoglobulin (Ig)A nephropathy. Clin. Exp. Immunol. 169, 148–155 (2012). PubMed DOI PMC

Medjeral-Thomas, N. R. et al. Progressive IgA nephropathy is associated with low circulating mannan-binding lectin-associated serine protease-3 (MASP-3) and increased glomerular factor H-related protein 5 (FHR5) deposition. Kidney Int. Rep. 3, 426–438 (2018). PubMed DOI

Paunas, T. I. F. et al. Glomerular abundance of complement proteins characterized by proteomic analysis of laser-captured microdissected glomeruli associates with progressive disease in IgA nephropathy. Clin. Proteom. 14, 30 (2017). DOI

Koopman, J. J. E., van Essen, M. F., Rennke, H. G., de Vries, A. P. J. & van Kooten, C. Deposition of the membrane attack complex in healthy and diseased human kidneys. Front. Immunol. 11, 599974 (2020). PubMed DOI

Selvaskandan, H., Shi, S., Twaij, S., Cheung, C. K. & Barratt, J. Monitoring immune responses in IgA nephropathy: biomarkers to guide management. Front. Immunol. 11, 572754 (2020). PubMed DOI PMC

Cho, B. S., Kim, S. D., Choi, Y. M. & Kang, H. H. School urinalysis screening in Korea: prevalence of chronic renal disease. Pediatr. Nephrol. 16, 1126–1128 (2001). PubMed DOI

Murakami, M. Screening for proteinuria and hematuria in school children – methods and results. Acta Paediatr. Jpn. 32, 682–689 (1990). PubMed DOI

Rivera, F., Lopez-Gomez, J. M. & Perez-Garcia, R., Spanish Registry of Glomerulonephritis. Clinicopathologic correlations of renal pathology in Spain. Kidney Int. 66, 898–904 (2004). PubMed DOI

Gutierrez, E. et al. Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy. Clin. J. Am. Soc. Nephrol. 2, 51–57 (2007). PubMed DOI

Tissandie, E. et al. Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases. Kidney Int. 80, 1352–1363 (2011). PubMed DOI

Saha, M. K., Julian, B. A., Novak, J. & Rizk, D. V. Secondary IgA nephropathy. Kidney Int. 94, 674–681 (2018). PubMed DOI PMC

Suzuki, K. et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int. 63, 2286–2294 (2003). PubMed DOI

Waldherr, R., Rambausek, M., Duncker, W. D. & Ritz, E. Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol. Dial. Transpl. 4, 943–946 (1989). DOI

Axelsen, R. A. et al. Renal glomerular lesions in unselected patients with cirrhosis undergoing orthotopic liver transplantation. Pathology 27, 237–246 (1995). PubMed DOI

Calmus, Y. et al. Prospective assessment of renal histopathological lesions in patients with end-stage liver disease: effects on long-term renal function after liver transplantation. J. Hepatol. 57, 572–576 (2012). PubMed DOI

Suzuki, H. et al. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int. 93, 700–705 (2018). A study suggesting that IgAN and IgA vasculitis with nephritis have a shared feature regarding galactose-deficient IgA1-oriented pathogenesis. PubMed DOI

Kauffmann, R. H., Herrmann, W. A., Meyer, C. J., Daha, M. R. & Van, Es,L. A. Circulating IgA-immune complexes in Henoch-Schönlein purpura. A longitudinal study of their relationship to disease activity and vascular deposition of IgA. Am. J. Med. 69, 859–866 (1980). PubMed DOI

Kiryluk, K. et al. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritis. Kidney Int. 80, 79–87 (2011). PubMed DOI PMC

Pillebout, E. & Sunderkotter, C. IgA vasculitis. Semin. Immunopathol. 43, 729–738 (2021). PubMed DOI

Ambruzs, J. M., Walker, P. D. & Larsen, C. P. The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin. J. Am. Soc. Nephrol. 9, 265–270 (2014). PubMed DOI

Ventura, A., Magazzu, G. & Greco, L. Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. SIGEP Study Group for Autoimmune Disorders in Celiac Disease. Gastroenterology 117, 297–303 (1999). PubMed DOI

Welander, A., Sundelin, B., Fored, M. & Ludvigsson, J. F. Increased risk of IgA nephropathy among individuals with celiac disease. J. Clin. Gastroenterol. 47, 678–683 (2013). PubMed DOI

Rollino, C., Vischini, G. & Coppo, R. IgA nephropathy and infections. J. Nephrol. 29, 463–468 (2016). PubMed DOI

Bu, R. et al. Clinicopathologic features of IgA-dominant infection-associated glomerulonephritis: a pooled analysis of 78 cases. Am. J. Nephrol. 41, 98–106 (2015). PubMed DOI

Huang, Z. et al. Clinicopathological and prognostic study of IgA-dominant postinfectious glomerulonephritis. BMC Nephrol. 22, 248 (2021). PubMed DOI PMC

Champtiaux, N. et al. Spondyloarthritis-associated IgA nephropathy. Kidney Int. Rep. 5, 813–820 (2020). PubMed DOI PMC

Makino, H. et al. Renal involvement in rheumatoid arthritis: analysis of renal biopsy specimens from 100 patients. Mod. Rheumatol. 12, 148–154 (2002). PubMed DOI

Grewal, S. K. et al. The risk of IgA nephropathy and glomerular disease in patients with psoriasis: a population-based cohort study. Br. J. Dermatol. 176, 1366–1369 (2017). PubMed DOI PMC

Le, W. et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol. Dial. Transpl. 27, 1479–1485 (2012). DOI

Reich, H. N., Troyanov, S., Scholey, J. W. & Cattran, D. C. Remission of proteinuria improves prognosis in IgA nephropathy. J. Am. Soc. Nephrol. 18, 3177–3183 (2007). PubMed DOI

Inker, L. A. et al. Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis. Am. J. kidney Dis. 68, 392–401 (2016). PubMed DOI

Knoop, T., Vikse, B. E., Mwakimonga, A., Leh, S. & Bjorneklett, R. Long-term outcome in 145 patients with assumed benign immunoglobulin A nephropathy. Nephrol. Dial. Transpl. 32, 1841–1850 (2017). DOI

Pitcher, D. et al. Long-term outcomes in IgA nephropathy. Clin. J. Am. Soc. Nephrol. 18, 727–738 (2023). PubMed DOI

Roberts, I. S. et al. the Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 76, 546–556 (2009). PubMed DOI

Trimarchi, H. et al. Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 91, 1014–1021 (2017). PubMed DOI

Coppo, R. et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 86, 828–836 (2014). PubMed DOI PMC

Itami, S., Moriyama, T., Miyabe, Y., Karasawa, K. & Nitta, K. A novel scoring system based on Oxford classification indicating steroid therapy use for IgA nephropathy. Kidney Int. Rep. 7, 99–107 (2022). PubMed DOI

Cambier, A., Troyanov, S., Tesar, V. & Coppo, R., Validation Study of Oxford Classification (VALIGA) Group. Indication for corticosteroids in IgA nephropathy: validation in the European VALIGA cohort of a treatment score based on the Oxford classification. Nephrol. Dial. Transpl. 37, 1195–1197 (2022). DOI

Barbour, S. J. et al. Updating the international IgA nephropathy prediction tool for use in children. Kidney Int. 99, 1439–1450 (2021). PubMed DOI

Barbour, S. J. et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern. Med. 179, 942–952 (2019). This study reports a new risk prediction tool in IgAN. PubMed DOI PMC

Barbour, S. J. et al. Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy. Kidney Int. 102, 160–172 (2022). This study reports an updated version of the risk prediction tool in IgAN that can be applied up to 2 years after biopsy. PubMed DOI

Haaskjold, Y. L. et al. Validation of two IgA nephropathy risk-prediction tools using a cohort with a long follow-up. Nephrol. Dial. Transpl. 38, 1183–1191 (2023). DOI

Rauen, T. et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N. Engl. J. Med. 373, 2225–2236 (2015). To our knowledge, this is the first of the latest clinical trials studying the value of corticosteroids in IgAN. PubMed DOI

Floege, J. & Feehally, J. Treatment of IgA nephropathy and Henoch-Schönlein nephritis. Nat. Rev. Nephrol. 9, 320–327 (2013). PubMed DOI

Cheng, J. et al. ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials. Int. J. Clin. Pract. 63, 880–888 (2009). This meta-analysis investigated the effects of RAASi in IgAN. PubMed DOI

Lie, D. N. W. et al. Long-term outcomes of add-on direct renin inhibition in IgA nephropathy: a propensity score-matched cohort study. J. Nephrol. 36, 407–416 (2023). PubMed DOI

Hayashi, K., Nagahama, T., Oka, K., Epstein, M. & Saruta, T. Disparate effects of calcium antagonists on renal microcirculation. Hypertens. Res. 19, 31–36 (1996). PubMed DOI

Ruggenenti, P., Perna, A., Benini, R. & Remuzzi, G. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J. Am. Soc. Nephrol. 9, 2096–2101 (1998). PubMed DOI

Park, H. C. et al. Effect of losartan and amlodipine on proteinuria and transforming growth factor-β1 in patients with IgA nephropathy. Nephrol. Dial. Transpl. 18, 1115–1121 (2003). DOI

Demarie, B. K. & Bakris, G. L. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann. Intern. Med. 113, 987–988 (1990). PubMed DOI

Mickisch, O. et al. Calcium antagonists in chronic renal failure. Undesirable effects on glomerular hemodynamics? [German]. Dtsch. Med. Wochenschr. 113, 1546–1548 (1988). PubMed DOI

Berthoux, F., Mariat, C. & Maillard, N. Overweight/obesity revisited as a predictive risk factor in primary IgA nephropathy. Nephrol. Dial. Transpl. 28, iv160–iv166 (2013). DOI

Wang, Q. et al. Impact of body mass index on primary immunoglobulin A nephropathy prognosis: a systematic review and meta-analysis. Int. Urol. Nephrol. 54, 1067–1078 (2022). PubMed DOI

Wang, S. et al. Cigarette smoking may accelerate the progression of IgA nephropathy. BMC Nephrol. 22, 239 (2021). PubMed DOI PMC

Nuffield Department of Population Health Renal Studies, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400, 1788–1801 (2022). DOI

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04573478 (2023).

Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219–2229 (2020). PubMed DOI

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05047263 (2023).

Rauen, T. et al. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 98, 1044–1052 (2020). PubMed DOI

Lv, J. et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 327, 1888–1898 (2022). This is the latest cinical trial studying the value of corticosteroids in IgAN. PubMed DOI PMC

Seikrit, C., Stamellou, E., Rauen, T. & Floege, J. TESTING the effects of corticosteroids in patients with IgA nephropathy. Nephrol. Dial. Transpl. 37, 1786–1788 (2022). DOI

Zhang, Y. M., Lv, J. C., Wong, M. G., Zhang, H. & Perkovic, V. Glucocorticoids for IgA nephropathy-pro. Kidney Int. 103, 666–669 (2023). PubMed DOI

Cheung, C. K. & Barratt, J. First do no harm: systemic glucocorticoids should not be used for the treatment of progressive IgA nephropathy. Kidney Int. 103, 669–673 (2023). PubMed DOI

Fellstrom, B. C. et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet 389, 2117–2127 (2017). PubMed DOI

Barratt, J. et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 103, 391–402 (2023). This is the clinical trial testing TRF-budesonide in patients with IgAN, the first drug approved for IgAN. PubMed DOI

Ismail, G. et al. Budesonide versus systemic corticosteroids in IgA nephropathy: a retrospective, propensity-matched comparison. Medicine 99, e21000 (2020). PubMed DOI PMC

Sun, L., Zi, X., Wang, Z. & Zhang, X. The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy. BMC Nephrol. 24, 63 (2023). PubMed DOI PMC

Maes, B. D. et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int. 65, 1842–1849 (2004). PubMed DOI

Frisch, G. et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol. Dial. Transpl. 20, 2139–2145 (2005). DOI

Tang, S. C. et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int. 77, 543–549 (2010). PubMed DOI

Hou, J. H. et al. Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial. Am. J. Kidney Dis. 69, 788–795 (2017). PubMed DOI

Huerta, A. et al. Corticosteroids and mycophenolic acid analogues in immunoglobulin A nephropathy with progressive decline in kidney function. Clin. Kidney J. 15, 771–777 (2022). PubMed DOI

Hou, F. F. et al. Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial. JAMA Netw. Open. 6, e2254054 (2023). PubMed DOI

Liu, L. J. et al. Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial. Am. J. Kidney Dis. 74, 15–22 (2019). PubMed DOI

Tang, C. et al. Long-term safety and efficacy of hydroxychloroquine in patients with IgA nephropathy: a single-center experience. J. Nephrol. 35, 429–440 (2022). PubMed DOI

Lafayette, R. A. et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J. Am. Soc. Nephrol. 28, 1306–1313 (2017). PubMed DOI

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05065970 (2023).

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05799287 (2023).

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04716231 (2021).

Lv, J. et al. Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int. Rep. 8, 499–506 (2023). PubMed DOI

Barratt, J. et al. Randomized phase II JANUS study of atacicept in patients with IgA nephropathy and persistent proteinuria. Kidney Int. Rep. 7, 1831–1841 (2022). PubMed DOI PMC

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04287985 (2023).

US National Library of Medicine. Clinicaltrials.gov https://clinicaltrials.gov/study/NCT03945318 (2023).

Barratt, J. et al. POS-109 interim results of phase 1 and 2 trials to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of BION-1301 in patients with IgA nephropathy [abstract POS-109]. Kidney Int. Rep. 7 (Suppl. 2), S46 (2022). DOI

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT02062684 (2017).

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT02112838?tab=history&a=10 (2019).

Tam, W. K. F. et al. Spleen tyrosine kinase (SYK) inhibition in IgA nephropathy: a global, phase II, randomised placebo-controlled trial of fostamatinib [abstract SUN-036]. Kidney Int. Rep. 7 (Suppl. 7), S168 (2019). DOI

Kateifides, A., Garlo, K., Rice, K., Spoerri, N. & Najafian, N. A phase 2 study evaluating the efficacy and safety of ravulizumab in patients with immunoglobulin A (IgA) nephropathy or proliferative lupus nephritis (LN) [abstract WCN23-0140]. Kidney Int. Rep. 8 (Suppl. 3), S54–S55 (2023). DOI

Barratt, J. Exploratory results from the phase 2 study of cemdisiran in patients with IgA nephropathy [abstract FR-OR67]. Presented at Kidney Week 2022 www.asn-online.org/education/kidneyweek/2022/program-abstract.aspx?controlId=3797891 (2022).

Barratt, J. Efficacy and safety of iptacopan in IgA nephropathy: results of a randomized double-blind placebo-controlled phase 2 study at 6 months [abstract POS-546]. Kidney Int. Rep. 7 (Suppl. 2), S236 (2022). DOI

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03373461 (2023).

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04578834 (2023).

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03453619 (2023).

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04014335 (2023).

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT02682407 (2020).

Lafayette, R. A. et al. Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy. Kidney Int. Rep. 5, 2032–2041 (2020). PubMed DOI PMC

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03608033 (2019).

Chemouny, J. M. et al. Modulation of the microbiota by oral antibiotics treats immunoglobulin A nephropathy in humanized mice. Nephrol. Dial. Transpl. 34, 1135–1144 (2019). DOI

Di Leo, V. et al. Rifaximin as a potential treatment for IgA nephropathy in a humanized mice model. J. Pers. Med. 11, 309 (2021). PubMed DOI PMC

Tan, J. et al. Probiotics ameliorate IgA nephropathy by improving gut dysbiosis and blunting NLRP3 signaling. J. Transl. Med. 20, 382 (2022). PubMed DOI PMC

Lauriero, G. et al. Fecal microbiota transplantation modulates renal phenotype in the humanized mouse model of IgA nephropathy. Front. Immunol. 12, 694787 (2021). PubMed DOI PMC

Zhao, J. et al. Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports. Ren. Fail. 43, 928–933 (2021). PubMed DOI PMC

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05182775 (2022).

Lv, J. et al. Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J. Am. Soc. Nephrol. 24, 2118–2125 (2013). PubMed DOI PMC

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 100, S1–S276 (2021). DOI

Audemard-Verger, A. et al. Characteristics and management of IgA vasculitis (Henoch-Schönlein) in adults: data from 260 patients included in a French multicenter retrospective survey. Arthritis Rheumatol. 69, 1862–1870 (2017). PubMed DOI

Leung, A. K. C., Barankin, B. & Leong, K. F. Henoch-Schönlein purpura in children: an updated review. Curr. Pediatr. Rev. 16, 265–276 (2020). PubMed DOI

Ozen, S. et al. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis – the SHARE initiative. Rheumatology 58, 1607–1616 (2019). PubMed DOI

Coppo, R. Treatment of IgA nephropathy in children: a land without KDIGO guidance. Pediatr. Nephrol. 36, 491–496 (2021). A very good review about the treatment of IgAN in children. PubMed DOI

Clayton, P., McDonald, S. & Chadban, S. Steroids and recurrent IgA nephropathy after kidney transplantation. Am. J. Transpl. 11, 1645–1649 (2011). DOI

Vasilica, C. et al. Identifying information needs of patients with IgA nephropathy using an innovative social media-stepped analytical approach. Kidney Int. Rep. 6, 1317–1325 (2021). PubMed DOI PMC

Feldman, D. L et al. Voice of the patient: report on the externally led patient-focused drug development meeting on IgA nephropathy. National Kidney Foundation https://www.igan.org/wp-content/uploads/2021/01/VOP_IgAN_12-7-20__FNL.pdf (2019).

Zaour, N., Mayländer, M., Walda, S, George, A.T. Patient journey, perceptions, and burden associated with immunoglobulin a nephropathy (IgAN): a qualitative study [abstract PUB159]. Presented at Kidney Week 2020 www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controlId=3444184 (2020).

Davis, R. S. Fc receptor-like molecules. Annu. Rev. Immunol. 25, 525–560 (2007). PubMed DOI

Croft, M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu. Rev. Immunol. 28, 57–78 (2010). PubMed DOI PMC

Lu, M. M. et al. Association of TNFSF4 polymorphisms with systemic lupus erythematosus: a meta-analysis. Mod. Rheumatol. 23, 686–693 (2013). PubMed DOI

Lucientes-Continente, L., Marquez-Tirado, B. & Goicoechea de Jorge, E. The factor H protein family: the switchers of the complement alternative pathway. Immunol. Rev. 313, 25–45 (2023). PubMed DOI

Ruben, S. M. et al. I-Rel: a novel rel-related protein that inhibits NF-kappa B transcriptional activity. Genes. Dev. 6, 745–760 (1992). PubMed DOI

Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A. & Bluestone, J. A. CD28 costimulation: from mechanism to therapy. Immunity 44, 973–988 (2016). PubMed DOI PMC

Nam, S. & Lim, J. S. Essential role of interferon regulatory factor 4 (IRF4) in immune cell development. Arch. Pharm. Res. 39, 1548–1555 (2016). PubMed DOI

Shaffer, A. L., Emre, N. C., Romesser, P. B. & Staudt, L. M. IRF4: immunity. malignancy! therapy? Clin. Cancer Res. 15, 2954–2961 (2009). PubMed DOI PMC

Khodadadi, L., Cheng, Q., Radbruch, A. & Hiepe, F. The maintenance of memory plasma cells. Front. Immunol. 10, 721 (2019). PubMed DOI PMC

Adamaki, M. et al. Implication of IRF4 aberrant gene expression in the acute leukemias of childhood. PLoS ONE 8, e72326 (2013). PubMed DOI PMC

Lynch, R. C., Gratzinger, D. & Advani, R. H. Clinical impact of the 2016 update to the WHO lymphoma classification. Curr. Treat. Options Oncol. 18, 45 (2017). PubMed DOI

Redondo, M. J., Fain, P. R. & Eisenbarth, G. S. Genetics of type 1A diabetes. Recent. Prog. Horm. Res. 56, 69–89 (2001). PubMed DOI

Murray, J. A. et al. HLA DQ gene dosage and risk and severity of celiac disease. Clin. Gastroenterol. Hepatol. 5, 1406–1412 (2007). PubMed DOI PMC

Dyment, D. A., Ebers, G. C. & Sadovnick, A. D. Genetics of multiple sclerosis. Lancet Neurol. 3, 104–110 (2004). PubMed DOI

Varney, M. D. et al. HLA DPA1, DPB1 alleles and haplotypes contribute to the risk associated with type 1 diabetes: analysis of the Type 1 Diabetes Genetics Consortium families. Diabetes 59, 2055–2062 (2010). PubMed DOI PMC

Yang, L., Lu, P., Yang, X., Li, K. & Qu, S. Annexin A3, a calcium-dependent phospholipid-binding protein: implication in cancer. Front. Mol. Biosci. 8, 716415 (2021). PubMed DOI PMC

Marin, N. D. & Garcia, L. F. The role of CD30 and CD153 (CD30L) in the anti-mycobacterial immune response. Tuberculosis 102, 8–15 (2017). PubMed DOI

Kennedy, M. K., Willis, C. R. & Armitage, R. J. Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 118, 143–152 (2006). PubMed DOI PMC

Picornell, Y. et al. TNFSF15 is an ethnic-specific IBD gene. Inflamm. Bowel Dis. 13, 1333–1338 (2007). PubMed DOI

Bertin, J. et al. CARD9 is a novel caspase recruitment domain-containing protein that interacts with BCL10/CLAP and activates NF-κB. J. Biol. Chem. 275, 41082–41086 (2000). PubMed DOI

Gross, O. et al. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 442, 651–656 (2006). PubMed DOI

Evans, D. M. et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat. Genet. 43, 761–767 (2011). PubMed DOI PMC

Fan, S., Liu, H. & Li, L. The REEP family of proteins: molecular targets and role in pathophysiology. Pharmacol. Res. 185, 106477 (2022). PubMed DOI

Ellinghaus, D. et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am. J. Hum. Genet. 90, 636–647 (2012). PubMed DOI PMC

Human Protein Atlas. ZMIZ1. Human Protein Atlas https://www.proteinatlas.org/ENSG00000108175-ZMIZ1 (2019).

Jia, D. et al. OVOL guides the epithelial-hybrid-mesenchymal transition. Oncotarget 6, 15436–15448 (2015). PubMed DOI PMC

Roca, H. et al. Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer. PLoS ONE 8, e76773 (2013). PubMed DOI PMC

Lecerf, K. et al. Case report and review of the literature: immune dysregulation in a large familial cohort due to a novel pathogenic RELA variant. Rheumatology 62, 347–359 (2022). PubMed DOI PMC

Garrett-Sinha, L. A. Review of Ets1 structure, function, and roles in immunity. Cell Mol. Life Sci. 70, 3375–3390 (2013). PubMed DOI PMC

Hom, G. et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N. Engl. J. Med. 358, 900–909 (2008). PubMed DOI

Holtschke, T. et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87, 307–317 (1996). PubMed DOI

Hu, X. et al. IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia. Cancer Res. 71, 2882–2891 (2011). PubMed DOI PMC

Maecker, H. et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell 123, 931–944 (2005). PubMed DOI

Burkly, L. C. TWEAK/Fn14 axis: the current paradigm of tissue injury-inducible function in the midst of complexities. Semin. Immunol. 26, 229–236 (2014). PubMed DOI

Tangye, S. G., Bryant, V. L., Cuss, A. K. & Good, K. L. BAFF, APRIL and human B cell disorders. Semin. Immunol. 18, 305–317 (2006). PubMed DOI

Corneth, O. B. J., Neys, S. F. H. & Hendriks, R. W. Aberrant B cell signaling in autoimmune diseases. Cells 11, 3391 (2022). PubMed DOI PMC

Byrjalsen, A. et al. Nationwide germline whole genome sequencing of 198 consecutive pediatric cancer patients reveals a high incidence of cancer prone syndromes. PLoS Genet. 16, e1009231 (2020). PubMed DOI PMC

Bakema, J. E. & van Egmond, M. The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity. Mucosal Immunol. 4, 612–624 (2011). PubMed DOI

Wang, J. et al. Leukemia inhibitory factor, a double-edged sword with therapeutic implications in human diseases. Mol. Ther. 31, 331–343 (2023). PubMed DOI

Sun, X., Zhan, M., Sun, X., Liu, W. & Meng, X. C1GALT1 in health and disease. Oncol. Lett. 22, 589 (2021). PubMed DOI PMC

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05097989 (2023).

Floege, J., Johnson, R. J. & Feehally, J. Comprehensive Clinical Nephrology 4th edn (Elsevier, 2010).

Wehbi, B., Pascal, V., Zawil, L., Cogne, M. & Aldigier, J. C. History of IgA nephropathy mouse models. J. Clin. Med. 10, 3142 (2021). PubMed DOI PMC

Monteiro, R. C. & Suzuki, Y. Are there animal models of IgA nephropathy? Semin. Immunopathol. 43, 639–648 (2021). PubMed DOI

Suzuki, H. & Suzuki, Y. Murine models of human IgA nephropathy. Semin. Nephrol. 38, 513–520 (2018). PubMed DOI

Wyatt, R. J. et al. IgA nephropathy: long-term prognosis for pediatric patients. J. Pediatr. 127, 913–919 (1995). PubMed DOI

Nozawa, R. et al. Clinicopathological features and the prognosis of IgA nephropathy in Japanese children on long-term observation. Clin. Nephrol. 64, 171–179 (2005). PubMed DOI

Coppo, R. Pediatric IgA nephropathy: clinical and therapeutic perspectives. Semin. Nephrol. 28, 18–26 (2008). PubMed DOI

Fassbinder, W. et al. Combined report on regular dialysis and transplantation in Europe, XX, 1989. Nephrol. Dial. Transpl. 6, 5–35 (1991).

Coppo, R. & Robert, T. IgA nephropathy in children and in adults: two separate entities or the same disease? J. Nephrol. 33, 1219–1229 (2020). PubMed DOI

Zhong, X. & Ding, J. Diagnosis and treatment of IgA nephropathy and IgA vasculitis nephritis in Chinese children. Pediatr. Nephrol. 38, 1707–1715 (2023). PubMed DOI

Coppo, R. Pediatric IgA nephropathy in Europe. Kidney Dis. 5, 182–188 (2019). DOI

Uffing, A., Hullekes, F., Riella, L. V. & Hogan, J. J. Recurrent glomerular disease after kidney transplantation: diagnostic and management dilemmas. Clin. J. Am. Soc. Nephrol. 16, 1730–1742 (2021). PubMed DOI PMC

Briganti, E. M., Russ, G. R., McNeil, J. J., Atkins, R. C. & Chadban, S. J. Risk of renal allograft loss from recurrent glomerulonephritis. N. Engl. J. Med. 347, 103–109 (2002). PubMed DOI

O’Shaughnessy, M. M. et al. Kidney transplantation outcomes across GN subtypes in the United States. J. Am. Soc. Nephrol. 28, 632–644 (2017). PubMed DOI

Cosio, F. G. & Cattran, D. C. Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation. Kidney Int. 91, 304–314 (2017). PubMed DOI

Moroni, G. et al. The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival. Nephrol. Dial. Transpl. 28, 1305–1314 (2013). DOI

Floege, J. & Gröne, H. J. Recurrent IgA nephropathy in the renal allograft: not a benign condition. Nephrol. Dial. Transpl. 28, 1070–1073 (2013). DOI

Uffing, A. et al. Recurrence of IgA nephropathy after kidney transplantation in adults. Clin. J. Am. Soc. Nephrol. 16, 1247–1255 (2021). PubMed DOI PMC

Alachkar, N. et al. Evaluation of the modified Oxford score in recurrent IgA nephropathy in North American kidney transplant recipients: the Banff Recurrent Glomerulonephritis Working Group Report. Transplantation 107, 2055–2063 (2023). PubMed DOI